Madrigal Pharmaceuticals Reports 2017 First Quarter Financial ResultsMay 11, 2017
Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196April 3, 2017
Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)February 23, 2017
Press Release History
Website Developed by Alan Leff Associates, Inc.